Jorge Julio Castillo MD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Physician

450 Brookline AveBoston, MA 02215
Phone+1 617-632-6045
Fax+1 617-582-8608

Dr. Castillo is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Castillo's full profile Already have an account?

Summary

Dr. Castillo was born in Peru, received his medical degree in Mexico City, and completed his Internal Medicine and Hematology & Oncology training at the University of Massachusetts and Brown University, respectively. Dr. Castillo is an Associate Professor at Harvard Medical School and serves as the Clinical Director of the Bing Center for Waldenström Macroglobulinemia at the Dana-Farber Cancer Institute. Dr. Castillo is also the principal investigator in a series of innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Dr. Castillo is a member of the NCCN Committee for Myeloma, Amyloidosis and Waldenström Macroglobulinemia. He has authored more than 275 peer-reviewed articles and has published his research in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Blood.

Education & Training

Rhode Island Hospital/Brown University HealthFellowship, Hematology and Medical Oncology, 2005 - 2008
MetroWest Medical CenterResidency, Internal Medicine, 2002 - 2005
Autonomous Metropolitan University XochimilcoClass of 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2013 - 2028
NH State Medical License 2023 - 2028
RI State Medical License 2005 - 2014
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Robert A. Kyle Award International Workshop for Waldenstrom Macrolgobulinemia, 2022
Innovation Dana-Farber Cancer Institute, 2022

Clinical Trials

Dasatinib In Waldenström Macroglobulinemia Start of enrollment: 2019 Nov 04
TERMINATED
PHASE1
Roles: Sponsor-Investigator, Contact, Principal Investigator
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
TERMINATED
PHASE2
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy Start of enrollment: 2021 Nov 16
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Contact, Sponsor-Investigator, Principal Investigator

Publications & Presentations

PubMed

Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.
Dominic Pizzarella, Amanda Kofides, John M Hatcher, Xia Liu, Alberto Guijosa
Blood Advances. 2026-07-14
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia.
Jorge J Castillo, Andrew R Branagan, Alberto Guijosa, Gottfried von Keudell, Andres Ramirez-Gamero
American Journal of Hematology. 2026-06-01
3 citations
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenström macroglobulinemia.
Hao Sun, Romanos Sklavenitis-Pistofidis, Shirong Liu, Xia Liu, Nicholas Tsakmaklis
Blood. 2026-05-14